<\/strong><\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2015-07-02", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-07-02T12:15:21.077Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-06-29", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Asthma: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what assessment he has made of the cost effectiveness of prescribing medicines for asthma patients; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4130", "label" : {"_value" : "Biography information for Baroness Ritchie of Downpatrick"}
}
, "tablingMemberConstituency" : {"_value" : "South Down"}
, "tablingMemberPrinted" : [{"_value" : "Ms Margaret Ritchie"}
], "uin" : "4661"}
, {"_about" : "http://data.parliament.uk/resources/384473", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/384473/answer", "answerText" : {"_value" : "
The NHS mandate for 2015-16 says that every patient with a long-term condition, including asthma and other respiratory conditions, should be offered a personalised care action plan. They and their families or carers should know the right medications to use at the right times and how to use them, and to understand the importance of monitoring their condition and how to do this.<\/p>
<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/127", "label" : {"_value" : "Biography information for Lord Prior of Brampton"}
}
, "answeringMemberPrinted" : {"_value" : "Lord Prior of Brampton"}
, "dateOfAnswer" : {"_value" : "2015-06-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-06-29T14:51:48.807Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-06-22", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Asthma: Drugs"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty\u2019s Government what steps they are taking to ensure that patients with asthma receive the right medication.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1796", "label" : {"_value" : "Biography information for Lord Taylor of Warwick"}
}
, "tablingMemberPrinted" : [{"_value" : "Lord Taylor of Warwick"}
], "uin" : "HL684"}
, {"_about" : "http://data.parliament.uk/resources/381490", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/381490/answer", "answerText" : {"_value" : "
There have been no recent discussions between the Secretary of State and the British Medical Association or other medical bodies on possible adverse effects of the use of inhalers for the treatment of asthma.<\/p>
<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
}
, "answeringMemberConstituency" : {"_value" : "Battersea"}
, "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
, "dateOfAnswer" : {"_value" : "2015-06-24", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-06-24T11:21:35.273Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-06-16", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Asthma: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what discussions he has had with (a) the British Medical Association and (b) other medical bodies on possible adverse effects of the use of inhalers for the treatment of asthma.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "2670"}
, {"_about" : "http://data.parliament.uk/resources/100876", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/100876/answer", "answerText" : {"_value" : "
Information on National Health Service expenditure on drugs for the treatment of asthma in primary and secondary care is in the table.<\/p>
<\/p>
<\/strong><\/p> <\/p>
Drugs for the treatment of osteoporosis have been defined as those included in the following British National Formulary sections:<\/p>
<\/p>
3.1.1 Adrenoceptor agonists<\/p>
<\/p>
3.1.2 Antimuscarinic bronchodilators<\/p>
<\/p>
3.1.3 Theophylline<\/p>
<\/p>
3.2 Corticosteroids<\/p>
<\/p>
3.3.1 Cromoglicate and related therapy<\/p>
<\/p>
3.3.2 Leukotriene receptor antagonists<\/p>
<\/p>
3.4.2 Allergen immunotherapy (omalizumab only)<\/p>
<\/p>
<\/p>
<\/p>
Cost of drugs for the treatment of asthma, England1<\/sup><\/p><\/td><\/tr>Drug name<\/p><\/td> | Primary Care (£ millions)<\/p><\/td> | Secondary Care (£ millions)<\/p><\/td><\/tr> | 2009<\/p><\/td> | 2010<\/p><\/td> | 2011<\/p><\/td> | 2012<\/p><\/td> | 2013<\/p><\/td> | 2009<\/p><\/td> | 2010<\/p><\/td> | 2011<\/p><\/td> | 2012<\/p><\/td> | 2013<\/p><\/td><\/tr> | Aclidinium Bromide<\/p><\/td> | -<\/p><\/td> | -<\/p><\/td> | -<\/p><\/td> | 0.02<\/p><\/td> | 1.62<\/p><\/td> | -<\/p><\/td> | -<\/p><\/td> | -<\/p><\/td> | 0.00<\/p><\/td> | 0.03<\/p><\/td><\/tr> | Aminophylline<\/p><\/td> | 1.25<\/p><\/td> | 1.18<\/p><\/td> | 1.12<\/p><\/td> | 1.08<\/p><\/td> | 1.05<\/p><\/td> | 0.30<\/p><\/td> | 0.29<\/p><\/td> | 0.21<\/p><\/td> | 0.23<\/p><\/td> | 0.22<\/p><\/td><\/tr> | Beclometasone Dipropionate<\/p><\/td> | 84.26<\/p><\/td> | 87.72<\/p><\/td> | 90.30<\/p><\/td> | 97.56<\/p><\/td> | 102.39<\/p><\/td> | 1.62<\/p><\/td> | 1.53<\/p><\/td> | 1.41<\/p><\/td> | 1.49<\/p><\/td> | 1.42<\/p><\/td><\/tr> | Budesonide<\/p><\/td> | 140.35<\/p><\/td> | 149.03<\/p><\/td> | 158.82<\/p><\/td> | 169.14<\/p><\/td> | 177.00<\/p><\/td> | 1.29<\/p><\/td> | 1.14<\/p><\/td> | 1.14<\/p><\/td> | 1.27<\/p><\/td> | 1.41<\/p><\/td><\/tr> | Budesonide/ Formoterol<\/p><\/td> | -<\/p><\/td> | -<\/p><\/td> | -<\/p><\/td> | -<\/p><\/td> | -<\/p><\/td> | 2.75<\/p><\/td> | 2.94<\/p><\/td> | 2.89<\/p><\/td> | 3.10<\/p><\/td> | 3.29<\/p><\/td><\/tr> | Ciclesonide<\/p><\/td> | 0.84<\/p><\/td> | 0.95<\/p><\/td> | 1.03<\/p><\/td> | 1.12<\/p><\/td> | 1.25<\/p><\/td> | 0.01<\/p><\/td> | 0.02<\/p><\/td> | 0.02<\/p><\/td> | 0.02<\/p><\/td> | 0.03<\/p><\/td><\/tr> | Fluticasone<\/p><\/td> | 366.24<\/p><\/td> | 380.56<\/p><\/td> | 387.89<\/p><\/td> | 392.95<\/p><\/td> | 396.10<\/p><\/td> | 1.00<\/p><\/td> | 0.93<\/p><\/td> | 0.91<\/p><\/td> | 1.00<\/p><\/td> | 0.99<\/p><\/td><\/tr> | Fluticasone/ Salmeterol<\/p><\/td> | -<\/p><\/td> | -<\/p><\/td> | -<\/p><\/td> | -<\/p><\/td> | -<\/p><\/td> | 11.46<\/p><\/td> | 11.56<\/p><\/td> | 10.69<\/p><\/td> | 10.82<\/p><\/td> | 10.48<\/p><\/td><\/tr> | Formoterol Fumarate<\/p><\/td> | 5.18<\/p><\/td> | 4.87<\/p><\/td> | 4.68<\/p><\/td> | 4.85<\/p><\/td> | 4.93<\/p><\/td> | 0.10<\/p><\/td> | 0.08<\/p><\/td> | 0.07<\/p><\/td> | 0.06<\/p><\/td> | 0.06<\/p><\/td><\/tr> | Glycopyrronium Bromide<\/p><\/td> | -<\/p><\/td> | -<\/p><\/td> | -<\/p><\/td> | 0.01<\/p><\/td> | 2.30<\/p><\/td> | 0.58<\/p><\/td> | 0.62<\/p><\/td> | 0.70<\/p><\/td> | 0.79<\/p><\/td> | 1.00<\/p><\/td><\/tr> | Indacaterol Maleate<\/p><\/td> | -<\/p><\/td> | 0.04<\/p><\/td> | 0.30<\/p><\/td> | 0.92<\/p><\/td> | 1.47<\/p><\/td> | -<\/p><\/td> | 0.00<\/p><\/td> | 0.00<\/p><\/td> | 0.02<\/p><\/td> | 0.04<\/p><\/td><\/tr> | Ipratropium Bromide<\/p><\/td> | 16.15<\/p><\/td> | 15.02<\/p><\/td> | 13.74<\/p><\/td> | 10.32<\/p><\/td> | 8.61<\/p><\/td> | 2.74<\/p><\/td> | 2.84<\/p><\/td> | 2.59<\/p><\/td> | 2.65<\/p><\/td> | 2.70<\/p><\/td><\/tr> | Mometasone Furoate<\/p><\/td> | 0.36<\/p><\/td> | 0.31<\/p><\/td> | 0.26<\/p><\/td> | 0.23<\/p><\/td> | 0.21<\/p><\/td> | 0.76<\/p><\/td> | 0.71<\/p><\/td> | 0.61<\/p><\/td> | 0.63<\/p><\/td> | 0.67<\/p><\/td><\/tr> | Montelukast<\/p><\/td> | 38.91<\/p><\/td> | 43.01<\/p><\/td> | 46.96<\/p><\/td> | 51.71<\/p><\/td> | 31.31<\/p><\/td> | 0.98<\/p><\/td> | 1.02<\/p><\/td> | 1.03<\/p><\/td> | 1.16<\/p><\/td> | 0.81<\/p><\/td><\/tr> | Omalizumab<\/p><\/td> | 0.00<\/p><\/td> | 0.01<\/p><\/td> | 0.03<\/p><\/td> | 0.15<\/p><\/td> | 0.12<\/p><\/td> | 5.97<\/p><\/td> | 9.22<\/p><\/td> | 12.16<\/p><\/td> | 14.65<\/p><\/td> | 17.86<\/p><\/td><\/tr> | Salbutamol<\/p><\/td> | 83.15<\/p><\/td> | 82.64<\/p><\/td> | 60.58<\/p><\/td> | 60.37<\/p><\/td> | 59.95<\/p><\/td> | 3.78<\/p><\/td> | 3.77<\/p><\/td> | 3.36<\/p><\/td> | 3.38<\/p><\/td> | 3.29<\/p><\/td><\/tr> | Salmeterol<\/p><\/td> | 48.80<\/p><\/td> | 45.16<\/p><\/td> | 41.87<\/p><\/td> | 36.72<\/p><\/td> | 34.04<\/p><\/td> | 0.87<\/p><\/td> | 0.74<\/p><\/td> | 0.59<\/p><\/td> | 0.53<\/p><\/td> | 0.47<\/p><\/td><\/tr> | Terbutaline Sulphate<\/p><\/td> | 8.61<\/p><\/td> | 8.20<\/p><\/td> | 7.61<\/p><\/td> | 7.43<\/p><\/td> | 7.18<\/p><\/td> | 0.18<\/p><\/td> | 0.16<\/p><\/td> | 0.14<\/p><\/td> | 0.14<\/p><\/td> | 0.15<\/p><\/td><\/tr> | Theophylline<\/p><\/td> | 2.18<\/p><\/td> | 2.17<\/p><\/td> | 2.15<\/p><\/td> | 2.22<\/p><\/td> | 2.26<\/p><\/td> | 0.12<\/p><\/td> | 0.11<\/p><\/td> | 0.11<\/p><\/td> | 0.11<\/p><\/td> | 0.11<\/p><\/td><\/tr> | Tiotropium<\/p><\/td> | 113.61<\/p><\/td> | 129.98<\/p><\/td> | 149.81<\/p><\/td> | 169.35<\/p><\/td> | 185.24<\/p><\/td> | 5.69<\/p><\/td> | 6.03<\/p><\/td> | 6.22<\/p><\/td> | 6.64<\/p><\/td> | 6.87<\/p><\/td><\/tr> | Zafirlukast<\/p><\/td> | 0.79<\/p><\/td> | 0.71<\/p><\/td> | 0.71<\/p><\/td> | 0.70<\/p><\/td> | 0.69<\/p><\/td> | 0.01<\/p><\/td> | 0.01<\/p><\/td> | 0.01<\/p><\/td> | 0.01<\/p><\/td> | 0.01<\/p><\/td><\/tr> | Other drugs2<\/sup><\/p><\/td>0.90<\/p><\/td> | 0.79<\/p><\/td> | 0.66<\/p><\/td> | 0.62<\/p><\/td> | 0.60<\/p><\/td> | 0.04<\/p><\/td> | 0.07<\/p><\/td> | 0.15<\/p><\/td> | 0.26<\/p><\/td> | 0.46<\/p><\/td><\/tr> | Total<\/p><\/td> | 911.6<\/p><\/td> | 952.3<\/p><\/td> | 968.5<\/p><\/td> | 1,007.5<\/p><\/td> | 1,018.3<\/p><\/td> | 40.3<\/p><\/td> | 43.8<\/p><\/td> | 45.0<\/p><\/td> | 49.0<\/p><\/td> | 52.4<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> 1 <\/sup>Cost of drugs at NHS list price not taking account of discounts, dispensing costs, fees or prescription charges income. Totals may not add up due to rounding.<\/p> <\/p> 2<\/sup> Other drugs include Azelastine/Fluticasone, Bambuterol Hydrochloride, Beclometasone/ Formoterol, Cromoglicic Acid, Fenoterol Hydrobromide, Fenoterol/Ipratropium Bromide, Fluticasone/ Formoterol, Nedocromil Sodium, Orciprenaline Sulfate and Sodium Cromoglicate.<\/p> <\/p> Source:<\/p> <\/p> Prescription Cost Analysis (PCA) provided by the Health and Social Care Information Centre (primary care)<\/p> <\/p> Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary care)<\/p> <\/p> <\/p> <\/p> Since some drugs are prescribed to treat more than one condition and as the condition for which a drug is prescribed is not collected, it is not possible to separate the different conditions for which a drug may have been prescribed. The information provided may therefore include costs from the prescribing of these drugs for conditions other than for asthma.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-10-29T17:13:01.0657405Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-24", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Asthma: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how much has been spent on the prescription of asthma drugs in the NHS in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester West"}
, "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
], "uin" : "211846"}
, {"_about" : "http://data.parliament.uk/resources/100885", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/100885/answer", "answerText" : {"_value" : " The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p> <\/p> <\/p> <\/p> £ million<\/em><\/p> <\/p> | <\/td> | 2009-10<\/p><\/td> | 2010-11<\/p><\/td> | 2011-12<\/p><\/td> | 2012-13<\/p><\/td> | 2013-14<\/p><\/td><\/tr> | Asthma<\/p><\/td><\/tr> | Medical Research Council<\/p><\/td> | 22.2 <\/del>6.6<\/ins><\/p><\/td>17.5 <\/del>5.3<\/ins><\/p><\/td>17.2<\/del> 4.5<\/ins><\/p><\/td>19.4<\/del> 3.6<\/ins><\/p><\/td>18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>Other Research Councils and Innovate UK<\/p><\/td> | 0.0<\/p><\/td> | 0.1<\/p><\/td> | 0.3<\/p><\/td> | 1.5<\/p><\/td> | 0.8<\/p><\/td><\/tr> | National Institute for Health Research<\/p><\/td> | 2.6<\/p><\/td> | 3.4<\/p><\/td> | 2.4<\/p><\/td> | 3.4<\/p><\/td> | 3.8<\/p><\/td><\/tr> | Total<\/p><\/td> | 24.8<\/del> 9.2<\/ins><\/p><\/td>21.0<\/del> 8.8<\/ins><\/p><\/td>19.9<\/del> 7.2<\/ins><\/p><\/td>24.3 <\/del>8.5<\/ins><\/p><\/td>23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr>Motor Neurone Research<\/p><\/td><\/tr> | Medical Research Council<\/p><\/td> | 7.0<\/p><\/td> | 7.5<\/p><\/td> | 4.2<\/p><\/td> | 4.1<\/p><\/td> | 3.6<\/p><\/td><\/tr> | Other Research Councils and Innovate UK<\/p><\/td> | 0.2<\/p><\/td> | 0.2<\/p><\/td> | 0.4<\/p><\/td> | 0.7<\/p><\/td> | 1.0<\/p><\/td><\/tr> | National Institute for Health Research<\/p><\/td> | 0.1<\/p><\/td> | 0.1<\/p><\/td> | 0.4<\/p><\/td> | 0.7<\/p><\/td> | 0.5<\/p><\/td><\/tr> | Total<\/p><\/td> | 7.3<\/p><\/td> | 7.8<\/p><\/td> | 5.0<\/p><\/td> | 5.5<\/p><\/td> | 5.1<\/p><\/td><\/tr> | Osteoporosis<\/p><\/td><\/tr> | Medical Research Council<\/p><\/td> | 6.2<\/p><\/td> | 5.4<\/p><\/td> | 5.1<\/p><\/td> | 4.6<\/p><\/td> | 5.9<\/p><\/td><\/tr> | Other Research Councils and Innovate UK<\/p><\/td> | 0.0<\/p><\/td> | 0.0<\/p><\/td> | 0.1<\/p><\/td> | 0.4<\/p><\/td> | 1.0<\/p><\/td><\/tr> | National Institute for Health Research<\/p><\/td> | 0.3<\/p><\/td> | 0.7<\/p><\/td> | 0.8<\/p><\/td> | 1.3<\/p><\/td> | 1.8<\/p><\/td><\/tr> | Total<\/p><\/td> | 6.5<\/p><\/td> | 6.1<\/p><\/td> | 6.0<\/p><\/td> | 6.3<\/p><\/td> | 8.7<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p> <\/p> <\/p> <\/p> Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p> <\/p> <\/p> <\/p> Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
, "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100885/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
}
, "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:29.113Z", "_datatype" : "dateTime"}
], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-24", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Asthma: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how much the Government has spent on the development of new drugs to treat the symptoms of asthma in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester West"}
, "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
], "uin" : "211885"}
], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 7, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}
|
|
|
|
|
|
|
|
|
|
|
| | |